TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Coherus Biosciences ( (CHRS) ) is now available.
On June 30, 2025, Coherus Oncology, Inc. received a deficiency notice from Nasdaq due to its stock price falling below $1.00 per share for 30 consecutive business days. By September 5, 2025, the company regained compliance with Nasdaq’s listing requirements, ensuring its continued presence on the Nasdaq Global Market.
The most recent analyst rating on (CHRS) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Coherus Biosciences stock, see the CHRS Stock Forecast page.
Spark’s Take on CHRS Stock
According to Spark, TipRanks’ AI Analyst, CHRS is a Neutral.
Coherus Biosciences faces significant financial challenges, with declining revenue and negative cash flows being the most critical issues. While technical indicators show some short-term bullish momentum, valuation remains unattractive due to ongoing losses. The earnings call provided some optimism with strategic repositioning and pipeline developments, but risks such as potential delisting and competitive pressures weigh heavily on the stock’s outlook.
To see Spark’s full report on CHRS stock, click here.
More about Coherus Biosciences
Coherus Biosciences operates in the biotechnology industry, focusing on oncology treatments and biosimilar products.
Average Trading Volume: 1,365,081
Technical Sentiment Signal: Sell
Current Market Cap: $149.9M
For a thorough assessment of CHRS stock, go to TipRanks’ Stock Analysis page.